Imaging Contrast

Contrast agents are injected into patients to help enhance images to make it easier for radiologists distinguish specific areas of the body from surrounding tissues. The most commonly used agents are iodinated contrast dye for computed tomography (CT), interventional cath lab angiography,  RF fluoroscopy, and in surgical OR procedures. MRI scans typically use gadolinium-based contrast agents. Ultrasound and echocardiography (cardiac ultrasound) imaging use contrast agents composed of microscopic bubbles to enhance images that otherwise would be suboptimal.

RSS icon
With the shortage, which pertains specifically to all formulations and concentrations of GE Healthcare’s Omnipaque (iohexol), expected to last until mid-June, several organizations have eluded that conservation efforts are of critical importance.#contrastshortage #CTcontrast #iodinatedcontrast

GE provides update on contrast media shortage

The COVID lockdowns at the Shanghai plant began on March 31, and although the plant there has since resumed operations, they are not yet at 100% capacity.

May 18, 2022
With the shortage, which pertains specifically to all formulations and concentrations of GE Healthcare’s Omnipaque (iohexol), expected to last until mid-June, several organizations have eluded that conservation efforts are of critical importance.#contrastshortage #CTcontrast #iodinatedcontrast

Preserving contrast media supplies: 7 ACR recommendations

With the shortage, which pertains specifically to all formulations and concentrations of GE Healthcare’s Omnipaque (iohexol), expected to last until mid-June, several organizations have alluded that conservation efforts are of critical importance.

May 9, 2022

Be prepared: IV contrast media shortage could last up to 8 weeks

All formulations and concentrations of GE Healthcare’s Omnipaque (iohexol) are expected to be in short supply until mid-June due to COVID lockdowns where the contrast is manufactured.

May 6, 2022
Displaying 9 - 11 of 11

Around the web

Cardiovascular Business
FDA warns against use of troubled heart devices, citing ‘continued concerns’ after multiple recalls

The agency is urging healthcare providers to transition away from these devices and seek out alternatives. It is even working with other manufacturers to try and get similar products on the market as quickly as possible. 

Cardiovascular Business
The push for an independent cardiology board continues

Jeffrey Kuvin, MD, one of the leading voices behind efforts to create a new Board of Cardiovascular Medicine, spoke with Cardiovascular Business about where things stand today.

AI in Healthcare
Biden Administration itemizes AI accomplishments to date

Half a year after President Biden officially directed federal agencies in the executive branch’s bailiwick to “seize the promise and manage the risks” of AI, the White House has posted a status report.

Design by Adaptive Theme
Trimed Popup
Trimed Popup